Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2023

Paik Paul K, Fan Pang-Dian, Qeriqi Besnik, Namakydoust Azadeh, Daly Bobby, Ahn Linda, Kim Rachel, Plodkowski Andrew, Ni Ai, Chang Jason, Fanaroff Rachel, Ladanyi Marc, de Stanchina Elisa, Rudin Charles M

Abstract excerpt

INTRODUCTION: Increased insight into the mutational landscape of squamous cell lung cancers (LUSCs) in the past decade has not translated into effective targeted therapies for patients with this disease. NRF2, encoded by NFE2L2, and its upstream regulator, KEAP1, control key aspects of redox balance and are frequently mutated in NSCLCs. METHODS: Here, we describe the specific potent activity of TAK-228, a TORC1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Glutaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kelch-Like ECH-Associated Protein 1

Share to Lung Neoplasms

Share to Mutation

Share to NF-E2-Related Factor 2

Source

Open in PubMed Open full text

Identifiers

PMID: 36240971
DOI: 10.1016/j.jtho.2022.09.225
PMCID: PMC10500888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.PMID 36240971Read ↗

Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.Semantic proximity Read ↗

STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerSemantic proximity Read ↗

KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.Semantic proximity Read ↗

KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.Semantic proximity Read ↗

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.Semantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.Semantic proximity Read ↗

Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and ProgressionSemantic proximity Read ↗

Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.Semantic proximity Read ↗

KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.